Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study

被引:60
作者
Bertelli, G
Venturini, M
Del Mastro, L
Bergaglio, M
Sismondi, P
Biglia, N
Venturini, S
Porcile, G
Pronzato, P
Costantini, M
Rosso, R
机构
[1] S Croce Gen Hosp, I-12100 Cuneo, Italy
[2] Natl Canc Inst, Genoa, Italy
[3] Univ Turin, Turin, Italy
[4] City Hosp, Massa, Italy
[5] City Hosp, Alba, Italy
[6] S Andrea Hosp, La Spezia, Italy
关键词
breast cancer; hot flashes; medroxyprogesterone acetate; megestrol acetate; postmenopausal symptoms; tamoxifen;
D O I
10.1093/annonc/mdf151
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hot flashes are frequent in postmenopausal breast cancer patients, especially when treated with tamoxifen. Estrogen replacement therapy is the most effective treatment for hot flashes, but its use is controversial in breast cancer survivors. Progestins may offer a good alternative for the control of hot flashes in this setting; in particular, oral megestrol acetate has been proven effective in a randomized, placebo-controlled clinical trial. With the aim of further improving these results, we have designed a randomized study comparing oral megestrol acetate with depot intramuscular (i.m.) medroxyprogesterone acetate (MPA) for the control of hot flashes in postmenopausal patients with a history of breast cancer. Patients and methods: Seventy-one postmenopausal patients were randomized to receive an i.m. injection of depot MPA 500 mg on days 1, 14 and 28, or oral megestrol acetate 40 mg daily for 6 weeks. Patients recorded daily the number and severity of their hot flashes; response was defined as a greater than or equal to50% decrease in the number and severity of hot flashes. Results: At week 6, hot flashes were reduced by 86% on average in the whole group of patients, without significant differences between the two progestins. Response was obtained by 75 and 67% of patients receiving MPA or megestrol, respectively P = 0.5). Responders were followed to assess maintenance of response (without further treatment), which was significantly better with i.m. MPA: in this group, 89% of responders still showed a benefit at week 24, compared with 45% in the megestrol group (P = 0.03). Conclusions: Our study shows that a short cycle of i.m. depot MPA injections provides significant and long-lasting relief from postmenopausal hot flashes in patients with a history of breast cancer, offering an alternative to estrogen replacement therapy or prolonged administration of oral megestrol.
引用
收藏
页码:883 / 888
页数:6
相关论文
共 17 条
  • [1] Prospective evaluation of vitamin E for hot flashes in breast cancer survivors
    Barton, DL
    Loprinzi, CL
    Quella, SK
    Sloan, JA
    Veeder, MH
    Egner, JR
    Fidler, P
    Stella, PJ
    Swan, DK
    Vaught, NL
    Novotny, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 495 - 500
  • [2] BULLOCK JL, 1975, OBSTET GYNECOL, V46, P165
  • [3] Carpenter JS, 1998, CANCER-AM CANCER SOC, V82, P1682, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.3.CO
  • [4] 2-8
  • [5] PREVALENCE OF MENOPAUSAL SYMPTOMS AMONG WOMEN WITH A HISTORY OF BREAST-CANCER AND ATTITUDES TOWARD ESTROGEN REPLACEMENT THERAPY
    COUZI, RJ
    HELZLSOUER, KJ
    FETTING, JH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) : 2737 - 2744
  • [6] FLEISS JL, 1981, STAT METHODS RATES
  • [7] Life after breast cancer: Understanding women's health-related quality of life and sexual functioning
    Ganz, PA
    Rowland, JH
    Desmond, K
    Meyerowitz, BE
    Wyatt, GE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 501 - 514
  • [8] TRANSDERMAL CLONIDINE FOR AMELIORATING TAMOXIFEN-INDUCED HOT FLASHES
    GOLDBERG, RM
    LOPRINZI, CL
    OFALLON, JR
    VEEDER, MH
    MISER, AW
    MAILLIARD, JA
    MICHALAK, JC
    DOSE, AM
    ROWLAND, KM
    BURNHAM, NL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) : 155 - 158
  • [9] Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
    Loprinzi, CL
    Kugler, JW
    Sloan, JA
    Mailliard, JA
    LaVasseur, BI
    Barton, DL
    Novotny, PJ
    Dakhil, SR
    Rodger, K
    Rummans, TA
    Christensen, BJ
    [J]. LANCET, 2000, 356 (9247) : 2059 - 2063
  • [10] MEGESTROL-ACETATE FOR THE PREVENTION OF HOT FLASHES
    LOPRINZI, CL
    MICHALAK, JC
    QUELLA, SK
    OFALLON, JR
    HATFIELD, AK
    NELIMARK, RA
    DOSE, AM
    FISCHER, T
    JOHNSON, C
    KLATT, NE
    BATE, WW
    ROSPOND, RM
    OESTERLING, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (06) : 347 - 352